MITF and melanoma: An increase in the expression of MITF was previously reported to contribute to tumor progression and resistance to BRAFi in a subset of melanomas (Johannessen et al, 2013), whereas low levels of MITF expression were shown to predict intrinsic MAPKi resistance (Konieczkowski et al, 2014; Muller et al, 2014), highlighting the dual function of this factor.